New research found patients with atopic dermatitis are up to 3 times more likely to experience depression and anxiety, especially when disease severity is high, and sleep is disrupted.
Ritlecitinib alone or with nbUVB therapy led to significant improvements in skin repigmentation among vitiligo patients, with more pronounced effects seen when both treatments were combined, according to a new phase 2b study.
The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.
The number of visits to dermatologists for atopic dermatitis and eczema may have increased during the summer months of 2023 following the Canadian wildfires.
A recent study investigated the prevalence of allergies and asthma among U.S. children during and before the COVID-19 pandemic, revealing changes in allergy prevalence and potential associations with pandemic-related lifestyle changes.